ANI Pharmaceuticals made a recommended offer to acquire Egetis Therapeutics in a deal valued at about $560 million when factoring in the company’s priority review voucher sale proceeds. The transaction includes $1.13 per Egetis share in cash and additional consideration for outstanding convertible debt and warrants, reflecting a reported 27% premium to the prior trading reference. Egetis’s lead therapy, Emcitate, has already been approved by the European Commission and later cleared by the FDA, and the buyer is projecting peak sales potential exceeding $300 million in the approved indication. The structure of the deal also explicitly monetizes Egetis’s priority review voucher for $190 million, adding to total value. For the biotech market, the agreement signals continued appetite for post-approval rare-disease assets and a growing willingness to underwrite regulatory acceleration instruments (priority review vouchers) as part of acquisition value. It also reinforces how companies can combine product economics (orphan exclusivity, patents, and label durability) with monetized regulatory tools to support downstream development and commercialization bets.